上周五，英国制药巨头阿斯利康（AstraZeneca, NASDAQ:AZN）宣布与中国石药集团（CSPC Pharmaceutical）达成一项潜在价值高达53.3亿美元的战略研究合作，旨在利用人工智能（AI）开发针对多种慢性疾病的新型口服疗法。

AstraZeneca and CSPC Pharmaceutical have signed a research deal worth up to USD 5.3 billion to co-develop oral therapies for chronic and immunological diseases. CSPC will lead discovery in China using ...

Cambridge: AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group ...

在制药行业，一则重磅消息正在引发广泛关注：全球知名制药公司阿斯利康（AstraZeneca）与中国领先的制药企业石药集团（CSPC）正式宣布达成一项深度战略合作。这一合作不仅代表着两大制药巨头的强强联手，更将对慢性疾病的治疗产生深远的影响。

Astra has agreed a deal that could be worth almost £4billion with a Chinese company to use AI in the production of new ...

AstraZeneca inks strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research: Cambridge, UK Saturday, June 14, 2025, 09:00 Hrs [IST] AstraZeneca has entered a ...

The latest health news covers FDA's extended review of KalVista's drug, UroGen's new bladder cancer treatment approval, ...

Tourist levels have angered those living in major European cities, who complain that Airbnb has pushed up rents and reduced ...

The collaboration will focus on identifying pre-clinical candidates for high-priority targets, including a small molecule ...

Anglo-Swedish pharma major AstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC ...

British drugmaker AstraZeneca unveiled on Friday an AI-assisted research partnership with Chinese counterpart CSPC ...

Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value ...